STOK Earnings Date: Mar 16, 2027 (Estimated) — Stoke Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is STOK's next earnings date?
Stoke Therapeutics, Inc. (STOK) is expected to report Q4 2026 earnings on Tuesday, March 16, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.96 on revenue of $8.2M.
How did STOK do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Stoke Therapeutics, Inc. posted EPS of -$1.08 versus the -$0.93 estimate, a miss of 16.2%. Revenue was $11.3M against a $8.2M estimate.
How much does STOK stock move after earnings?
STOK beat EPS estimates in 5 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 6.8% (up or down) in the day after earnings.
About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
🤖 AI Earnings Analysis
Stoke’s quarter was mixed but loss-heavy: revenue beat estimates at $11 million, yet was flat year over year, while EPS missed by $0.15 at -$1.08, underscoring continued biotech investment risk.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | -0.93 | -1.08 | -16.24% | $11.3M | ❌ Miss | — | — | — |
| 2026-08-03 | Q2 2026 | -0.78 | -0.93 | -19.23% | $9.3M | ❌ Miss | +7.14% | +9.03% | +4.50% |
| 2026-05-07 | Q1 2026 | -0.81 | -0.79 | +2.47% | $6.2M | ✅ Beat | +0.30% | -4.36% | -11.56% |
| 2025-11-04 | Q3 2025 | -0.58 | -0.65 | -12.07% | $10.6M | ❌ Miss | -9.94% | -0.91% | +22.53% |
| 2025-08-12 | Q2 2025 | -0.55 | -0.40 | +27.27% | $13.8M | ✅ Beat | +24.98% | +36.66% | +76.50% |
| 2025-03-18 | Q4 2024 | -0.54 | -0.18 | +66.67% | $22.6M | ✅ Beat | -1.44% | -7.89% | -13.89% |
| 2024-11-05 | Q3 2024 | -0.53 | -0.47 | +11.32% | $4.9M | ✅ Beat | -0.38% | +5.42% | -2.21% |
| 2024-08-07 | Q2 2024 | -0.55 | -0.46 | +16.36% | $4.8M | ✅ Beat | -3.65% | -0.42% | +6.47% |
Showing last 8 quarters.
Revenue by segment & region
By segment
FY2025 · $16.1M total · annual
| Segment | Share | Revenue | YoY | FY2025 |
|---|---|---|---|---|
| License | 71.4% | $11.5M | -60.9% | $11.5M |
| Service | 28.6% | $4.6M | -36.1% | $4.6M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.